Newsletters

[Advanced Materials] A pH and reactive oxygen species (ROS) dual-responsive autocatalytic release system was constructed to reverse the immunosuppressive microenvironment and potentiate colorectal cancer immunotherapy.

[UCLA Health] Researchers from the University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center were awarded a $3 million grant from the National Institutes of Health to improve follow-up care for colorectal cancer screening in underserved populations.

[Abivax] Abivax SA announced the first patient was enrolled in its Phase IIb ENHANCE-CD trial evaluating obefazimod in patients with Crohn’s disease.

[Cancer Research] Single cell multi-omics uncovered epigenetic alterations that accompany enteroendocrine cells (EEC) differentiation, identified STAT3 as a regulator of EEC specification, and discovered a rare cancer-specific cell type with enteric neuron-like characteristics.

[Nature News] One woman and two men with severe autoimmune conditions have gone into remission after being treated with bioengineered and CRISPR-modified immune cells1. The three individuals from China are the first people with autoimmune disorders to be treated with engineered immune cells created from donor cells, rather than ones collected from their own bodies.

[Burns & Trauma] Scientists summarizes the influence and contribution of both scaffold-based and external stimulus-based mechanical strategies for vascularization in tissue engineering and elucidates the underlying mechanisms involved.

[Nanoscale] In vivo CD56+ NK cell genetic engineering is hypothesized through the CD56-directed delivery of the pSMP-EzH2 shRNA plasmid encapsulated in chitosan nanoparticles.

[Curium] Curium announced that it has entered into a strategic partnership with PDRadiopharma, Inc, a wholly-owned subsidiary of PeptiDream, for the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T.

[Forbes] A “dangerously biased” combination of social factors and inadequate research is raising Black men’s already-heightened risk of developing prostate cancer, a UK charity has stated

[Prostate Cancer and Prostatic Diseases] This was a single-institution, single-arm, non-therapeutic, interventional trial of 166 men with biopsy-confirmed prostate cancer enrolled between 2014–2020. Patients were placed on a trial-mandated AS protocol including yearly multiparametric MRI, prostate biopsy, and 4Kscore followed for 48 months after diagnosis.

[Scientific Reports] Patients with prostate cancer who express PDIA2 high in particular have a bad prognosis in terms of progression-free survival. In addition, the upregulation of PDIA2 expression in prostate cancer patients was accompanied by higher Gleason scores, advanced tumor staging, lymph node metastasis, and elevated PSA levels.

[Nature Neuroscience] Researchers showed that microglia in prenatal mouse and human brain interact with nascent vasculature in an age-dependent manner and that ablation of these cells in mice reduced angiogenesis in the ganglionic eminences, which corresponded to the human germinal matrix.